Author:
Novello S.,Mazières J.,Oh I.-J.,de Castro J.,Migliorino M.R.,Helland Å.,Dziadziuszko R.,Griesinger F.,Kotb A.,Zeaiter A.,Cardona A.,Balas B.,Johannsdottir H.K.,Das-Gupta A.,Wolf J.
Reference22 articles.
1. Isolated central nervous system progression on crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?;Chun;Cancer Biol Ther,2012
2. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases;Costa;J Clin Oncol,2015
3. FDA Approval for Ceritinib. https://www.cancer.gov/about-cancer/treatment/drugs/fda-ceritinib (March 2018, date last accessed).
4. EMA Zykadia recommended for approval in advanced nonsmall-cell lung cancer. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/02/news_detail_002279.jsp&mid=WC0b01ac058004d5c1 (March 2018, date last accessed).
5. Ceritinib in ALK-positive metastatic NSCLC patients with progression on or intolerance to crizotinib;Stenger,2014
Cited by
247 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献